Ryosuke Higuchi, Itaru Takamisawa, Mamoru Nanasato, Shinichiro Doi, Shinya Okazaki, Harutoshi Tamura, Masaki Ishiyama, Hiroaki Yokoyama, Motoki Fukutomi, Shuichiro Takanashi, Mike Saji, Mitsuaki Isobe
Despite the overall expansion of transcatheter aortic valve implantation, procedure volume among low-risk patients has not consistently increased. Clinical trial eligibility, female sex, BMI, and albumin levels may refine risk stratification in Society of Thoracic Surgeons-defined low-risk patients. (Outcomes of transcatheter aortic valve implantation in Japanese patients with aortic stenosis: LAPLACE-TAVI registry; UMIN000031133).
BACKGROUND: Transcatheter aortic valve implantation is now indicated in low-risk patients following favorable outcomes in clinical trials and real-world registries.
OBJECTIVES: The authors aimed to investigate temporal trends and long-term outcomes in this population.
METHODS: Using a multicenter registry database (2010-2025), we stratified 5,691 patients by their Society of Thoracic Surgeons scores: low risk (<4%, n = 1,580 of 5,691 [27.8%]), intermediate risk (4% to 8%, n = 2,388 of 5,691 [42.0%]), and high risk (>8%, n = 1,723 of 5,691 [30.3%]). Low-risk patients were further classified according to clinical trial eligibility. The primary outcomes were crude 30-day and Kaplan-Meier-estimated 4-year all-cause mortalities.
RESULTS: The annual procedure volume among low-risk patients did not show a sustained increase and declined after peaking in 2022. Low-risk patients were younger, predominantly male, had a higher body mass index (BMI), fewer comorbidities, and fewer procedural complications. They also demonstrated higher rates of elective procedure and transfemoral access. Thirty-day mortality and procedural complication rates remained consistently low among the low-risk cohort; furthermore, 4-year mortality was the lowest among trial-eligible low-risk patients (overall follow-up: 2.2 years). Clinical trial eligibility criteria (frailty [HR: 2.43; 95% CI: 1.43-4.14; P = 0.003] and renal dysfunction [HR: 3.00; 95% CI: 1.46-6.20; P = 0.010]), female sex (HR: 0.62; 95% CI: 0.44-0.89; P = 0.009), BMI (HR: 0.94 per kg/m2; 95% CI: 0.90-0.98; P = 0.008), and albumin levels (HR: 0.52 per g/dL; 95% CI: 0.36-0.77; P = 0.001) were associated with all-cause mortality in low-risk patients.
CONCLUSIONS: Despite the overall expansion of transcatheter aortic valve implantation, procedure volume among low-risk patients has not consistently increased. Clinical trial eligibility, female sex, BMI, and albumin levels may refine risk stratification in Society of Thoracic Surgeons-defined low-risk patients. (Outcomes of transcatheter aortic valve implantation in Japanese patients with aortic stenosis: LAPLACE-TAVI registry; UMIN000031133).